MyoKardia initiated with an Outperform at BMO Capital. BMO Capital analyst George Farmer initiated MyoKardia with an Outperform rating and $85 price target. The analyst said he would be a buyer on his view of the potential of lead drug, mavacamten, for treatment of hypertrophic cardiomyopathy. He added that the recent stock pullback caused by the loss of Sanofi (SNY) as an entrenched partner, which he believes mostly had to do with Sanofi pipeline re-prioritization, creates an attractive entry point for investment in MyoKardia.
https://thefly.com/landingPageNews.php?id=2868301
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.